Abeona therapeutics announces progress update on pz-cel biologics license application (bla)

- on track for pdufa target action date of may 25, 2024 - cleveland, feb. 01, 2024 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) today announced, as part of the review process by the u.s. food and drug administration (fda) for the biologics license application (bla) for pz-cel (prademagene zamikeracel) for recessive dystrophic epidermolysis bullosa (rdeb), completion by the fda of both a bioresearch monitoring (bimo) inspection of abeona and the bla mid-cycle review meeting. the bimo inspection was conducted from january 22, 2024 through january 24, 2024 at abeona's headquarters in cleveland, ohio, and reviewed the conduct and practices that pertain to the clinical studies of pz-cel.
ABEO Ratings Summary
ABEO Quant Ranking